IRulya Therapeutics (IRLA) Cash from Financing (Quarterly): 108.93M

IRulya Therapeutics, Inc. (IRLA)

32.95 +1.33 (+4.21%) USD | NASDAQ | Oct 30, 16:00

33.50 +0.55 (+1.67%) After-Hours: 20:00

Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.

Date	Value
June 30, 2026	108.93M
March 31, 2026	9.443M
December 31, 2025	2.034M
September 30, 2025	1.376M
June 30, 2025	14.41M
March 31, 2025	0.087M
December 31, 2024	0.00
September 30, 2024	-5.00M
June 30, 2024	0.035M
March 31, 2024	0.19M
December 31, 2023	0.057M
September 30, 2023	0.01M
June 30, 2023	0.026M
March 31, 2023	0.05M
December 31, 2022	-0.018M
September 30, 2022	-0.005M
June 30, 2022	0.108M

Date	Value
March 31, 2022	0.622M
December 31, 2021	0.99M
September 30, 2021	4.705M
June 30, 2021	0.672M
March 31, 2021	0.441M
December 31, 2020	0.045M
September 30, 2020	0.09M
June 30, 2020	0.889M
March 31, 2020	117.85M
December 31, 2019	-0.53M
September 30, 2019	0.00
June 30, 2019	77.83M
March 31, 2019	0.064M
December 31, 2018
September 30, 2018
June 30, 2018	75.70M
March 31, 2018	0.238M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks